| Caryn Barnett |
Caryn Barnett is currently the Vice President-Clinical Operations at Chimerix, Inc. She previously worked as the Vice President-Clinical Operations at Advanced Accelerator Applications USA, Inc. Barnett has a graduate degree from Indiana University and an undergraduate degree from West Virginia University. |
| Thomas J. Riga |
Thomas J. Riga is currently the Chief Operating & Commercial Officer at Chimerix, Inc. Prior to his current position, he worked at Spectrum Pharmaceuticals, Inc. from 2013 to 2023, where he served as President, Chief Executive Officer & Director from 2021 to 2022. Riga received his undergraduate degree from St. Lawrence University. |
| Joshua E. Allen |
Joshua E. Allen is currently the Chief Technology Officer at Chimerix, Inc. Prior to his current position, he served as the Chief Scientific Officer at Oncoceutics, Inc. from 2003 to 2021. Dr. Allen holds a doctorate degree from the University of Pennsylvania. |
| Roy W. Ware |
Roy W. Ware is currently the Chief Manufacturing Technology Officer at Chimerix, Inc. He previously worked as a Principal at Serenex, Inc. Dr. Ware holds a doctorate degree from Wake Forest University, an MBA from Kenan-Flagler Business School, and an undergraduate degree from The University of North Carolina at Greensboro. |
| Michael T. Andriole |
Michael T. Andriole is currently the President, Chief Executive Officer & Director at Chimerix, Inc. Prior to his current position, he served as the Vice President-Corporate Business Development at Eli Lilly & Co. from 2014 to 2017. He also worked as the Chief Financial Officer at Endocyte, Inc. in 2017 and 2018. Mr. Andriole holds an MBA from Kelley School of Business and an undergraduate degree from Williams College of Business. |
| Michelle LaSpaluto |
Michelle LaSpaluto is currently the Chief Financial Officer at Chimerix, Inc. since 2023. Previously, she worked as the Senior Director-Accounting at AlphaVax, Inc. from 2000 to 2011. Ms. LaSpaluto completed her undergraduate degree at Michigan State University and holds an MBA from East Carolina University. |
| David Jakeman |
David Jakeman has held the following current jobs: Vice President-Finance & Accounting at Chimerix, Inc. and Principal at Ernst & Young LLP. He has an education background from The University of North Carolina at Charlotte and Kenan-Flagler Business School. |
| Allen Melemed |
Allen Melemed is currently the Chief Medical Officer at Chimerix, Inc. Prior to this, he worked at Eli Lilly & Co. for over 20 years, where his last position was Senior Director-Regulatory Affairs Oncology. Melemed received his undergraduate degree from the University of Minnesota, his MBA from The University of Chicago Booth School of Business, and his doctorate from the University of Minnesota Medical School. |
| Michael A. Alrutz |
Michael A. Alrutz is currently the Secretary, Senior Vice President & General Counsel at Chimerix, Inc. He previously worked as the General Counsel at Trimeris, Inc. from 2002 to 2011. He completed his undergraduate degree at the University of Pennsylvania, his graduate degree at Duke University School of Law, and his doctorate at the Sackler School of Graduate Biomedical Sciences. |
| Martha J. Demski |
Martha J. Demski is currently an Independent Director at Alpha Teknova, Inc., Lead Independent Director at Chimerix, Inc., and Independent Director at Equillium, Inc. She previously served as an Independent Director at ADMA Biologics, Inc., Adamas Pharmaceuticals LLC, Neothetics, Inc., and Bank of America Corp. She was also the Chief Financial Officer & Senior Vice President at Ajinomoto Althea, Inc., Chief Operating & Financial Officer at Sidney Kimmel Cancer Center, and Senior Vice President at US Trust. Ms. Demski's early career includes being the Chief Financial Officer & Vice President at Vical, Inc. She holds an undergraduate degree from Michigan State University and an MBA from The University of Chicago Booth School of Business. |
| Michael A. Sherman |
Michael A. Sherman is currently the Chairman at Chimerix, Inc. since 2023, an Independent Director at Werewolf Therapeutics, Inc. since 2021, and a Trustee and Director at The Children's Museum of Indianapolis, Inc. since 2012. Previously, he served as the President, Chief Executive Officer & Director at Endocyte, Inc. from 2017 to 2018. He was also an Independent Director at BioSpecifics Technologies Corp. in 2020, an Independent Director at Mead Johnson Nutrition Co. from 2015 to 2017, and the Vice President-Finance & Strategic Planning at Guidant Corp. from 2004 to 2006. Additionally, he worked as a Principal at Eli Lilly & Co. Mr. Sherman holds an undergraduate degree from DePauw University and an MBA from the Tuck School of Business at Dartmouth. |
| Victoria Vakiener |
Victoria Vakiener is an Independent Director at Arrowhead Pharmaceuticals, Inc. and Chimerix, Inc. She previously worked as Vice President at Janssen Pharmaceuticals, Inc., Chief Commercial Officer at Epizyme, Inc., and Vice President-Oncology Marketing at Janssen Oncology, Inc. She completed her undergraduate degree at Albright College. |
| Lisa L. Decker |
Lisa L. Decker is an Independent Director at Chimerix, Inc. since 2023 and the Chief Business Officer at IGM Biosciences, Inc. since 2021. Previously, she worked as the Associate Director-Technology Licensing at UMass Chan Medical School from 2000 to 2008. From 2008 to 2019, she served as the Vice President-Business Development at Nektar Therapeutics. She then became the Chief Business Officer at Atreca, Inc. from 2019 to 2021. Dr. Decker completed her undergraduate degree at the College of the Holy Cross (Massachusetts) and obtained a doctorate from Tufts University School of Medicine in 1998. |
| Fred A. Middleton |
Fred A. Middleton's current job(s) include Vice Chairman & Chief Business Officer at Altor BioScience Corp., Managing Director at Sanderling Management CO LLC, Director at Cylene Pharmaceuticals, Inc., Independent Director at Chimerix, Inc., Director at Actimis Pharmaceuticals, Inc., Managing Director at Middleton, McNeil & Mills Associates V LLC, Director at CalciMedica, Inc. (US), Director at TheraVida, Inc., Director at Lineagen, Inc., Independent Director at CalciMedica, Inc., Director at Asteres, Inc., Managing Director at Mesa Verde Ventures LLC, and Member at MIT Corp. (United States). Mr. Middleton's former job(s) include Chairman at Genteric, Inc., Chief Financial Officer & Director at Regeneron Pharmaceuticals, Inc., Director at Favrille, Inc., Independent Director at CardioNet LLC, Independent Director at Stereotaxis, Inc., Director at Axikin Pharmaceuticals, Inc., Director at Pacira Biosciences, Inc., Independent Director at Endocyte, Inc., Director at CoMentis, Inc., Director at HCW Biologics Inc., Director at ViaCyte, Inc., Chief Financial Officer & VP-Administration at Genentech, Inc., Vice President-Planning & Development at The Chase Manhattan Bank NA, Managing General Partner at Morgan Stanley & Co. LLC, and Consultant at McKinsey & Co., Inc.Mr. Middleton's education history includes an undergraduate degree from Massachusetts Institute of Technology in 1971 and an MBA from Harvard Business School in 1973. |
| Catherine Lynch Gilliss |
Catherine Lynch Gilliss is on the board of Chimerix, Inc. and Triangle Residential Options for Substance Abusers, Inc. and Dean & Professor-Nursing at The University of California, San Francisco and Member of North Carolina Institute of Medicine.
In the past she was President of North Carolina Foundation For Nursing, Professor at Helene Fuld Medical Center, President of American Academy of Nursing, President for National Organization of Nurse Practitioner Faculties, Vice Chancellor-Nursing Affairs at Duke University, Vice Chancellor-Nursing Affairs at Duke University Health System, Inc., Professor at Duke University School of Nursing and Professor & Dean at Yale School of Nursing.
Catherine Lynch Gilliss received a graduate degree from The Catholic University of America, a doctorate from The University of California, San Francisco and an undergraduate degree from Duke University. |
| Robert James Meyer |
Robert James Meyer is currently an Independent Director at Chimerix, Inc., an Associate Professor-Public Health Sciences at the University of Virginia, and a Principal-Drug & Biological Products at Greenleaf Health Inc. Previously, he served as an Independent Director at Translate Bio, Inc. from 2019 to 2021. He also held positions at the US Food & Drug Administration as the Director-Drug Evaluation & Research from 1999 to 2007, and at the Center for Drug Evaluation & Research as the Director-Office Drug Evaluation II from 1994 to 2007. Additionally, he was the Director of the Virginia Center For Translational & Regulatory Sciences from 2013 to 2017, and a Director at Correvio Pharma Corp. from 2015 to 2020. He worked at Merck & Co., Inc. and Merck Research Laboratories Massachusetts LLC as the VP, Head-Global Regulatory Strategy & Policy from 2007 to 2013. Furthermore, he served as a Trustee at The United States Pharmacopeia from 2015 to 2020. Dr. Meyer obtained his undergraduate degree from Lehigh University in 1980 and his doctorate degree from The University of Connecticut School of Medicine in 1988. |
| Clarence Patrick Machado |
Clarence Patrick Machado is the founder of Medivation, Inc. (founded in 1995) and Medivation LLC (California) (founded in 1995). He held the title of Director at both companies from 2014 to 2016. Mr. Machado's current job(s) include Chairman at Adverum Biotechnologies, Inc. (since 2017), Independent Director at Chimerix, Inc. (since 2014), Independent Director at Xenon Pharmaceuticals, Inc. (since 2020), Director at Turnstone Biologics, Inc., Independent Director at Arcus Biosciences, Inc. (since 2019), Director at Auransa, Inc., Director at Roivant Sciences, Inc., Director at ACELYRIN, Inc. (since 2021), and Member-Supervisory Board at Therachon Holding GmbH. Mr. Machado's former job(s) include Chairman at Armaron Bio Ltd., Independent Director at Inotek Pharmaceuticals Corp. (from 2016 to 2018), Director at Principia Biopharma, Inc. (from 2019 to 2020), Independent Director at Turning Point Therapeutics, Inc. (from 2019 to 2022), Independent Director at Roivant Sciences Ltd. (from 2016 to 2022), Independent Director at SCYNEXIS, Inc. (from 2015 to 2019), Independent Director at Endocyte, Inc. (in 2018), Chief Financial Officer, Director & Senior VP at Medivation Neurology LLC (from 2003 to 2004), Director at Sio Gene Therapies, Inc. (from 2017 to 2018), Director at Axovant Sciences, Inc. (from 2017 to 2018), Independent Director at Montes Archimedes Acquisition Corp., Independent Director at Turnstone Biologics Corp. (from 2018 to 2024), Chief Legal Counsel at Chiron Corp., Chief Financial Officer at Orion Acquisition Corp. II, Consultant at Cytyc Corp. (in 2002), Principal at Morrison & Foerster LLP, and Chief Financial Officer & Senior Vice President at Pro-Duct Health, Inc. (from 1998 to 2001). Mr. Machado's education includes an undergraduate degree from Santa Clara University (conferred in 1986) and a graduate degree from Harvard Law School (conferred in 1989). |
| Pratik S. Multani |
Pratik S. Multani is currently an Independent Director at Chimerix, Inc. and Erasca, Inc. He is also a Principal at the American Board of Internal Medicine. In addition, he serves as the Chief Medical Officer at Oric Pharmaceuticals, Inc. Dr. Multani previously held positions as a Senior Director-Medical Research & Development at Biogen, Inc. and as a Vice President-Clinical Development at Kalypsys, Inc. He also served as the Chief Medical Officer at Kanisa Pharmaceuticals, Inc. and Ignyta, Inc. Dr. Multani has an undergraduate degree from Yale University, a doctorate from Harvard Medical School, and a graduate degree from Harvard T.H. Chan School of Public Health. |
